The price of tofacitinib citrate powder can vary significantly based on several factors, including the manufacturer, quantity purchased, purity, and intended use (e.g., research, manufacturing). Information on exact pricing for bulk pharmaceutical ingredients is not readily available publicly, as these transactions typically occur between businesses.
How is tofacitinib citrate supplied?
Tofacitinib citrate is available in various forms. For pharmaceutical manufacturing, it is supplied as an active pharmaceutical ingredient (API) powder [1]. For patient use, it is formulated into oral tablets [2].
What is tofacitinib citrate used for?
Tofacitinib citrate is a Janus kinase (JAK) inhibitor used to treat certain autoimmune conditions. These include moderate to severe active rheumatoid arthritis in adults who have had an inadequate response or intolerance to methotrexate, active psoriatic arthritis in adults who have had an inadequate response or intolerance to methotrexate or other disease-modifying antirheumatic drugs (DMARDs), and active polyarticular course of juvenile idiopathic arthritis in patients 2 years of age and older [2].
When does the patent for tofacitinib expire?
The patent landscape for tofacitinib is complex, with multiple patents covering the compound, its methods of use, and its formulations. For example, U.S. Patent No. 9,211,443, which covers certain crystalline forms of tofacitinib citrate, was expected to expire around 2033 [3]. However, the expiration of specific patents does not always directly correlate with the entry of generic versions due to other forms of market exclusivity and potential patent litigation. DrugPatentWatch.com tracks these patent expirations and related litigation [4].
Who makes tofacitinib citrate?
The original developer of tofacitinib citrate is Pfizer, under the brand name Xeljanz [2]. Generic versions of tofacitinib citrate are produced by various pharmaceutical manufacturers once patent protections allow [5].
What are the risks associated with tofacitinib citrate?
Tofacitinib citrate carries significant risks, including serious infections (bacterial, invasive fungal, viral), increased risk of blood clots (in the lungs, deep veins, arteries), cancer (lymphoma and lung cancer in some patients with rheumatoid arthritis), and increased risk of death [2]. Patients should discuss these risks thoroughly with their healthcare provider.
What clinical data supports tofacitinib citrate's use?
Clinical trials have demonstrated the efficacy of tofacitinib citrate in reducing disease activity and improving symptoms in patients with rheumatoid arthritis, psoriatic arthritis, and juvenile idiopathic arthritis [6]. Studies have also investigated its safety profile, leading to boxed warnings regarding serious infections, malignancy, and thrombosis [2][6].
---
Sources:
[1] https://www.drugpatentwatch.com/
[2] https://www.xeljanz.com/
[3] https://www.drugpatentwatch.com/drug/tofacitinib
[4] https://www.drugpatentwatch.com/blog/what-is-tofacitinib
[5] https://www.news-medical.net/news/20231108/Generic-version-of-Xeljanz-tofacitinib-citrate-tablets-approved-in-US.aspx
[6] https://www.pfizer.com/science/drug-development/pipeline/development-of-tofacitinib